Johnson & Johnson Innovation
在场
Johnson & Johnson Innovation 的所有者是 Johnson & Johnson.
是其中之一......
- Forbes Global 2000 (#45);
- Fortune 500 (#42);
- Global Fortune 500 (#115);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Johnson & Johnson 是一家在股票代码 JNJ (US) 下上市的公司。
Johnson & Johnson 在 23 个国家有直接业务。Johnson & Johnson 拥有 65家子公司，其中包括 Abiomed、Ambrx 和 DePuy Synthes。
他们在：
涉及Johnson & Johnson的并购和融资。
- Johnson & Johnson 已收购 V-Wave (公布2024十月9号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024六月21号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024五月20号).
- Johnson & Johnson has announced the acquisition of Shockwave Medical (公布2024四月6号).
- Johnson & Johnson 已收购 Ambrx (公布2024一月11号).
- 查看更多"Johnson & Johnson"相关新闻 Hide news involving Johnson & Johnson
高管
查看带有其 29 名主要高管的组织结构图
Johnson & Johnson Innovation 搜索最多的简介
- Chris Picariello, President
- Michal Preminger, Head, East North America
- Melinda Richter, Global Head of JLabs
高管在Johnson & Johnson变化
- Scott Davis, Director, 正在办理退休 (新闻发布的2024九月11号).
- Kristen Mulholland 曾任 Head of Human Resources, Global Total Rewards, 将于 202410月1 升职为 Chief Human Resources Officer (新闻发布的2024八月26号).
- Peter Fasolo, Executive Vice President and Chief Human Resources Officer, 将于 202410月1 退休 (新闻发布的2024八月26号).
创建提醒
跟踪 Johnson & Johnson Innovation 的高管变动
生物技术
Johnson & Johnson 拥有 2,326 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
- Trace Neuroscience 刚刚宣布为 101 筹款数百万美元。 (公布2024十一月14号).
- AvenCell Therapeutics 刚刚宣布为 112 筹款数百万美元。 (公布2024十一月11号).
生物技术 行业的其他推荐联系人
消息
Johnson & Johnson Innovation 的最新新闻稿
- Paige Announces Collaboration to Deploy a Novel AI-Based Biomarker Test for Advanced Bladder Cancer in Clinical Settings
- Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains
- Locus Biosciences Announces $35 Million Financing
- Bioasis Enters Into Research Collaboration With Janssen
- Bioasis Enters Into Research Collaboration With Janssen
- ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes
- Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies | Fate Therapeutics, Inc.
- OrthoSpin Ltd. Raises up to US$5 Million in Series B Financing
- Concerto HealthAI Establishes Real-World Data and AI Collaboration with Janssen
- Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.
- View more press releases Close
通过电子邮件
